---
title: "LB Pharmaceuticals, Inc. (LBRX) Gets a Buy from Roth MKM"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282748371.md"
description: "Roth MKM analyst Boobalan Pachaiyappan has reiterated a Buy rating on LB Pharmaceuticals, Inc. (LBRX) with a price target of $31.00. Pachaiyappan, a 4-star analyst with an average return of 8.8% and a 45.45% success rate, focuses on the Healthcare sector. Additionally, Craig-Hallum also initiated coverage with a Buy rating and a $36.00 price target on the same stock."
datetime: "2026-04-14T21:18:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282748371.md)
  - [en](https://longbridge.com/en/news/282748371.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282748371.md)
---

# LB Pharmaceuticals, Inc. (LBRX) Gets a Buy from Roth MKM

Roth MKM analyst Boobalan Pachaiyappan reiterated a Buy rating on LB Pharmaceuticals, Inc. today and set a price target of $31.00.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Pachaiyappan is a 4-star analyst with an average return of 8.8% and a 45.45% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, Neurosense Therapeutics Ltd., and PolyPid.

In a report released on April 10, Craig-Hallum also initiated coverage with a Buy rating on the stock with a $36.00 price target.

### Related Stocks

- [LBRX.US](https://longbridge.com/en/quote/LBRX.US.md)
- [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md)
- [NRSN.US](https://longbridge.com/en/quote/NRSN.US.md)
- [PYPD.US](https://longbridge.com/en/quote/PYPD.US.md)
- [NRSNW.US](https://longbridge.com/en/quote/NRSNW.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)
- [LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)](https://longbridge.com/en/news/286648209.md)
- [Damora Therapeutics (DMRA) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/286678740.md)